Edgewise Therapeutics, Inc. · NASDAQ:EWTX
Edgewise Therapeutics — PPMD Connect Conference 2021
8 slides from Edgewise Therapeutics's conference presentation, June 2021
Slide 1: EDG-5506: A Novel Small Molecule to Protect Dystrophic Muscle
EDG-5506: A Novel Small Molecule to Protect Dystrophic Muscle PPMD Connect Conference June 23 – 26, 2021 Joanne M. Donovan, MD, PhD Chief Medical Officer
Slide 2: Disclaimer
Disclaimer Disclaimer This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statem
Slide 3: In Dystrophic Muscle, Everyday Use Triggers Muscle Damage that Ultimately Leads to Loss of Function
In Dystrophic Muscle, Everyday Use Triggers Muscle Damage that Ultimately Leads to Loss of Function When dystrophin is deficient or absent in Becker and Duchenne muscular dystrophy, the stress of everyday use of muscles triggers muscle damage that ultimately leads to loss of function. The myofibrils
Slide 4: Edgewise Approach: Protect Susceptible Muscle Fibers
Edgewise Approach: Protect Susceptible Muscle Fibers In dystrophic muscle, certain muscle fibers, the fast muscle fibers, are more susceptible to damage due to the lack of dystrophin We’ve designed an investigational therapy, EDG-5506, to protect fast muscle fibers from damage. Slow muscle fibers ar
Slide 5: EDG-5506 Targets Myosin, the Key Protein to Drive Muscle Contraction, but only in Fast Muscle Fibers
EDG-5506 Targets Myosin, the Key Protein to Drive Muscle Contraction, but only in Fast Muscle Fibers • The key protein in muscle producing contraction is called myosin • EDG-5506 selectively inhibits this protein in fast fibers only • Our goal is to limit myosin to a level that prevents breakdown bu
Slide 6: After Two Weeks of EDG-5506, CK Decreased While Activity Increased in a Dog Model of DMD
After Two Weeks of EDG-5506, CK, a Marker of Muscle Damage, Decreased, While Activity Increased in a Dog Model of DMD Decreased injury biomarker Increased activity measured (plasma CK) with an activity monitor Statistically significant difference Statistically significant difference Before dosing Af
Slide 7: The Product Candidate: EDG-5506
The Product Candidate: EDG-5506 • EDG-5506 is a small once daily tablet or liquid suspension o Potentially appropriate for any age and any mutation • Phase 1 in unaffected adults is ongoing • We are also enrolling adults with Becker for a short study to measure biomarkers and safety • We are plannin
Slide 8: Thank you!
Thank you! For questions or comments please email us! info@edgewisetx.com 8